English  |  正體中文  |  简体中文  |  總筆數 :2818629  
造訪人次 :  28133410    線上人數 :  1525
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"kong o"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 1-4 / 4 (共1頁)
1 
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2020-05-25T06:51:44Z Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study Im S.-A;Sohn J;Tripathy D;Chow L;Lee K.S;Jung K.H;Babu G;Im Y.-H;El Saghir N;Liu M.-C;Diaz-Padilla I;Alam J;Kong O;Miller M;Yen-Shen Lu; Im S.-A; Sohn J; Tripathy D; Chow L; Lee K.S; Jung K.H; Babu G; Im Y.-H; El Saghir N; Liu M.-C; Diaz-Padilla I; Alam J; Kong O; Miller M; YEN-SHEN LU
臺大學術典藏 2020-05-25T06:51:44Z Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study Im S.-A;Sohn J;Tripathy D;Chow L;Lee K.S;Jung K.H;Babu G;Im Y.-H;El Saghir N;Liu M.-C;Diaz-Padilla I;Alam J;Kong O;Miller M;Yen-Shen Lu; Im S.-A; Sohn J; Tripathy D; Chow L; Lee K.S; Jung K.H; Babu G; Im Y.-H; El Saghir N; Liu M.-C; Diaz-Padilla I; Alam J; Kong O; Miller M; YEN-SHEN LU
臺大學術典藏 2020-05-25T06:51:44Z Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis Bardia A;Campos-Gomez S;Hurvitz S.A;Yen-Shen Lu;Im S.-A;Franke F;Chow L;Wheatley-Price P;Melo Cruz F;Alam J;Kong O;Diaz-Padilla I;Miller M;Tripathy D.; Bardia A; Campos-Gomez S; Hurvitz S.A; YEN-SHEN LU; Im S.-A; Franke F; Chow L; Wheatley-Price P; Melo Cruz F; Alam J; Kong O; Diaz-Padilla I; Miller M; Tripathy D.
臺大學術典藏 2020-05-25T06:51:44Z Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis Bardia A;Campos-Gomez S;Hurvitz S.A;Yen-Shen Lu;Im S.-A;Franke F;Chow L;Wheatley-Price P;Melo Cruz F;Alam J;Kong O;Diaz-Padilla I;Miller M;Tripathy D.; Bardia A; Campos-Gomez S; Hurvitz S.A; YEN-SHEN LU; Im S.-A; Franke F; Chow L; Wheatley-Price P; Melo Cruz F; Alam J; Kong O; Diaz-Padilla I; Miller M; Tripathy D.

顯示項目 1-4 / 4 (共1頁)
1 
每頁顯示[10|25|50]項目